磁性纳米四氧化三铁协同顺铂作用于肺癌A549细胞的初步研究-东南大学学报医学版

磁性纳米四氧化三铁协同顺铂作用于肺癌A549细胞的初步研究

单位：东南大学附属中大医院肿瘤中心;

分类号：

出版年·卷·期（页码）：2009·28·第四期（297-301）

摘要：

目的:检测磁性纳米四氧化三铁(Nano-Fe3O4)联合顺铂(DDP)作用于人源肺腺癌细胞A549后相关凋亡抑制基因、耐药蛋白的表达,研究其增强化疗敏感度的机制。方法:用MTT法检测Nano-Fe3O4聚合DDP对A549细胞增殖凋亡的影响;流式细胞术分析凋亡细胞比例;RT-PCR检测抗凋亡基因bcl-2、survivin、ERCC1表达水平变化;蛋白印迹法分析耐药蛋白MRP及其表达率。结果:25μg.ml-1Nano-Fe3O4能有效增强DDP的细胞毒作用,提高A549的凋亡率;与单独用药组相比,Nano-Fe3O4联合DDP组的抗凋亡基因bcl-2、ERCC1和耐药蛋白MRP表达下调,差异具有统计学意义(P<0.05);survivin基因表达未见明显改变。结论:Nano-Fe3O4联合DDP可通过下调抗凋亡基因bcl-2、ERCC1及耐药蛋白MRP的表达,增强化疗药物敏感度。

参考文献：

[1]	Stewart DJ. Mechanism of resistance to cisplatin and car-boplatin[J] .Crit Rev Oncol Hematol, 2007, 63 (1) :12-31 .
[2]	Cheng T C, Manorek G, Samimi G et al. Identification of genes whose expression is associated with cisplatin resis- tance in human ovarian carcinoma cells .Cancer Chemo- ther Pharmacol, 2006, 58 (3) :384-395 .
[3]	Volm M, Koomagi R, Mattern J. Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma .Anticancer Res, 1996, 16(1) :213-217 .
[4]	Okouoyo S, Herzer K, Ucur E, et al. Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo .Int J Cancer, 2004, 108(4) :580-587 .
[5]	Carvalho A,Carmena M,Sambade C,et al. Survivin is re- quired for stable checkpoint activation in taxol-treated HeLa cells .J Cell Sci, 2003, 116(14) :2987-2998 .
[6]	R?del F, Frey B, Leitmann W, et al. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models .Int J Radiat Oncol Biol Phys, 2008, 71 (1) :247-255 .
[7]	Singhal S,Vachani A,Antin-Ozerkis D,et al. Prognostic implications of cell cycle,apoptosis,and angiogenesis biomarkers in non-small cell lung cancer:a review .Clin Cancer Res, 2005, 11 (11) :3974-3986 .
[8]	Rosel R, ,Danenberg KD, Alberda V, et al. Ribonucleotide Reductase Messenger RNA Expression and survival in Gemcitabine/ cisplatin-treated advanced non-small-cell lung cancer patients .Clin Cancer Res, 2004, 10 (4) :1318-1325 .
[9]	Benlloch M,Ortega A,Ferrer P. Acceleration of glutathione ef-flux and inhibition of gamma-glutamyltranspeptidase sensitize metastatic B16melanoma cells to endothelium-induced cytotoxici-ty[J] .Journal of Biological Chemistry, 2005, 280 (8) :6950-6959 .
[10]	Slodkowska J,Sikora J,Roszkowski,Sliz K,et al. Expression ofvascular endothelial growth factor and basic fibroblast growth factorreceptors in lung cancer[J] .Anal Quant Cytol Histol, 2000, 22 (5) :398-402 .
[11]	Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficiency against experimental drug-resistant cancer .Cancer Res, 2000, 60 :1878~1886 .
[12]	KimHR,KimS,Kim E,et al. Suppression of Nrf2-driven heme oxygenase-1enhances the chemosensitivity of lung cancer A549cells toward cisplatin[J] .Lung Cancer, 2008, 60 (1) :47-56 .
[13]	MORNET S,VEKRIS A,BONNET J,et al. DNA—magnetitenanocomposite materials[J] .Mater Leter, 2000, 42 (3) :183-188 .
[14]	GUO Y,ZANG Y J,YANG HC,et al. The expression and clin-ical significance of drugfast GAP-associated proteins and thep53,bcl-2 genes in lung cancer tissue[J] .Chin J Clin Oncol, 2005, 32 (18) :1037-1039 .
[15]	WANG Z H,HUA M W,ZHU Z T. The relationship betweenthe expression of Survivin in human non-small cell lung cancerand microvessel density[J] .The Chinese German Journal ofClinical Oncology, 2008, 7 (7) :387-389 .
[16]	RYAN B M,KONECNY G E,KAHLERTS,et al. Survivin ex-pression in breast cancer predicts clinical outcome and is asso-ciated with HER2,VEGF,urokinase plasminogen activator andPAI-1[J] .Annals of Oncology, 2006, 17 (4) :597-604 .
[17]	HWANG I G,AHN M J,PARK B B,et al. ERCC1 expressionas a prognostic marker in N2(+)nonsmall-cell lung cancerpatients treated with platinum-based neoadjuvant concurrentchemoradiotherapy[J] .Cancer, 2008, 113 (6) :1379-1386 .

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录